Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343120 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
A Phase 1 study of B-cell Malignancies, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT02343120 is a Phase 1 study of B-cell Malignancies that has completed, run by BeiGene. The registered enrollment target is 385 participants, above the 270-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02343120, a Phase 1 study of B-cell Malignancies, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
Conditions Studied
Interventions
- DRUG Zanubrutinib
Study Locations (20)
Victoria
- Monash Health - Clayton
- Austin Health - Heidelberg
- St Vincent's Hospital - Melbourne
- Peter MacCallum Cancer Centre, East Melbourne - Parkville
- Melbourne Health - Parkville
Other
- Policlinico S.Orsola Malpighi, AOU di Bologna - Bologna
- Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda - Milan
- North Shore Hospital - Auckland
- Dong-A University Medical Centre - Busan
- Inje University Busan Paik Hospital - Busan
New South Wales
- Concord Repatriation General Hospital - Concord
- St George Hospital - Sydney
- Westmead Hospital - Westmead
Arizona
- Banner MD Anderson Cancer Centre - Gilbert
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Texas
- M.D. Anderson Cancer Center - Houston
Queensland
- Princess Alexandra Hospital - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343120
The ClinicalTrials.gov registry entry for NCT02343120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 270-participant average among 6 other B-cell Malignancies trials with a reported enrollment target (43% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT02343120 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Victoria, Other, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02343120 about?
NCT02343120 is a clinical study titled "Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies". This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
What is the current status of trial NCT02343120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 385 participants. The study started on 2014-09-04. Estimated completion is 2021-03-31.
What conditions does trial NCT02343120 study?
This clinical trial studies the following conditions: B-cell Malignancies.
What interventions are being tested in trial NCT02343120?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT02343120?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02343120 being conducted?
This trial has 20 study locations across Arizona, Michigan, Minnesota, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
-
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.